CHF 155.20 MOVE.SW Medacta Group S.A. (SIX) intraday 11 Mar 2026: key earnings to watch

The MOVE.SW stock trades at CHF 155.20 intraday on 11 Mar 2026 ahead of Medacta Group S.A.’s scheduled earnings release on 13 Mar 2026. Investors will watch revenue trends, operating margin and guidance. Key metrics show EPS 4.31 and PE 36.29, while volume sits at 9,258.00 shares. This earnings spotlight links financials to near-term price action and sets expectations for post-report trading

MOVE.SW stock: earnings timetable and what to expect

Medacta (MOVE.SW) reports on 13 Mar 2026 after market hours, two trading days from today. The market will focus on organic revenue growth, guidance for 2026, and margin progression. Recent fiscal momentum includes net income per share 4.76 and strong operating cash flow growth of 42.61% year-over-year.

MOVE.SW stock valuation and key financial metrics

Valuation currently reads PE 36.29 and book value per share 21.29. Revenue per share is 32.39 and free cash flow per share is 1.36. These figures produce a price-to-sales ratio of 5.34 and price-to-book near 8.13, higher than healthcare peers. One implication is premium pricing for Medacta’s device portfolio despite a modest free cash flow yield of 0.78%.

MOVE.SW stock technicals and intraday trading cues

Intraday range today is CHF 152.40 to CHF 155.40 with previous close CHF 153.20. RSI sits near 50.08, and Bollinger middle band is 153.47, suggesting balanced momentum. Average volume is 16,008.00, so current 9,258.00 trades imply low liquidity. Traders should watch a break above CHF 160.01 (50-day average) for short-term bullish confirmation.

Analyst signals and Meyka AI grade for MOVE.SW stock

Meyka AI rates MOVE.SW with a score out of 100: 78.32 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst signals. Note the company score mixes strong ROE and ROA with weaker PE and PB relative to peers. Independent analyst consensus is limited, so the Meyka grade is a model-based view, not investment advice.

MOVE.SW stock risks and opportunities heading into earnings

Primary opportunities include continued adoption of personalized orthopedic tools and growth in North America and APAC. Financial growth shows EPS growth 54.01% last year. Key risks include inventory days of 466.37, which may pressure working capital, and a debt-to-equity ratio of 0.60. Expect investors to weigh margin guidance against capital spending plans.

Earnings catalysts and how results could move MOVE.SW stock

Watch three catalysts: revenue guidance, margin trajectory, and geographic sales mix. Upbeat guidance could lift the stock above the 50-day average CHF 160.01. Soft guidance or margin erosion could push price toward the 200-day average CHF 149.11. For supporting detail see company filings and market data at Medacta’s investor site Medacta Investor Relations and the SIX exchange overview SIX Swiss Exchange.

Final Thoughts

Key takeaways for MOVE.SW stock ahead of the 13 Mar 2026 report: the intraday price is CHF 155.20, and the shares trade at a premium valuation with PE 36.29 and price-to-book 8.13. Operational strengths include strong ROE 23.61% and improving cash flow. Inventory build and high capex remain watchpoints. Meyka AI’s forecast model projects a yearly target CHF 193.66, implying an upside of 24.82% versus current price. These forecasts are model-based projections and not guarantees. Traders should balance premium valuation against growth signals and use the earnings call to reassess guidance. For live monitoring use Meyka AI’s platform for real-time metrics and updates

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.